Decreased CSF Aβ40 and Aβ42 levels in candidates for anti-amyloid therapy with advanced MRI-visible perivascular spaces in the centrum semiovale | Synapse
March 3, 2026
Decreased CSF Aβ40 and Aβ42 levels in candidates for anti-amyloid therapy with advanced MRI-visible perivascular spaces in the centrum semiovale
Key Points
Decreased levels of CSF Aβ40 and Aβ42 indicate a significant finding in candidates for therapy.
CSF Aβ40 and Aβ42 levels were notably lower among those with advanced MRI-visible perivascular spaces.
Observational analysis assessed CSF levels and MRI findings in relation to anti-amyloid therapy.
Implication highlights the potential for these biomarkers in identifying suitable candidates for intervention.